2022 CSID | Azf's decision -making emergence, achieving the new crown weapon

The countdown to register for the joint tour of the four -city subway in the north! 8 special columns are about to start!

The domestic first new crown oral medicine Azf's fixed tablet is included in the new crown diagnosis and treatment plan

The fast and accurate "dynamic clearing" is an effective magic weapon for my country's control of the epidemic. In the critical period and state of the prevention and control of this epidemic, the first domestic new crown oral medicine Azf will emerge. On July 25, 2022, Azf was approved by the State Drug Administration (NMPA) approved to add adaptive disease to the treatment of adult patients in ordinary new coronary virus pneumonia (COVID-19), which will provide the domestic and global epidemic prevention and control provision Tackling forces.

On August 9, 2022, the National Health and Health Commission issued the "Notice on Treatment of Azf's Fixed Sets into the Diagnosis and Treatment of New Coronatte Viruses Pneumonia" and stated that in accordance with the conditions of the State Drug Administration, Azf's fixed chip increase the treatment of new coronary viruses for the treatment of new coronary virus In order to further improve the approval of pneumonia adaptation applications, in order to further improve the new type of coronary virus pneumonia antiviral treatment plan, after research, the drug was included in the "New Coronary Virus Pneumonia Diagnosis Plan (Ninth Edition)".

This means that Azf will be one of the powerful "weapons" for future resistance, providing patients with more effective choices. In the case where the situation of the epidemic prevention and control is still severe, Azf's fixed film has assisted Henan, Hainan, Xinjiang and other places in many places to build an epidemic prevention and control barrier and go all out to protect the health of the people.

The topic of the infection annual meeting will attract attention, and thoroughly interpret the clinical data of Azf

The 17th National Academic Conference of Infectious Diseases is one of the largest and most influential academic conferences in the field of infectious diseases in my country. It has attracted many top experts from all over the country to conduct the latest research progress of new coronary virus infections, viral hepatitis and liver diseases. After in -depth exchanges and discussions, it fully demonstrated the results of the domestic outstanding homemade clinical research, and received warm response and active support.

The prevention and treatment of new crown pneumonia is one of the focus of the discussion of this conference. Among them, the clinical efficacy and safety data displayed in the Azf's special seminar have attracted strong attention.

As the first anti -new crown oral medication in my country, what is its clinical efficacy and safety?

During the Azf's topic conference, the new crown indication research and development led Professor PI Zhang Fujie from the mechanism of action and domestic and foreign phase III clinical trial data to confirm the effectiveness and safety of Azf's treatment in the treatment of new crown:

Precision blocking virus replication: Azfdin special effects on RDRP, precise blocking the new coronal virus RNA replication

Quickly inhibit the virus: Azf will quickly inhibit the virus in 5 days, significantly reduces the virus load of minor and ordinary new crown patients

Effective improvement of clinical symptoms: Azfdin's phase III clinical data confirmed that the proportion of clinical improvement on the seventh day was 3.7 times that of the control group, reaching the results of clinical excellent effects; , Three days faster than the control group

Good safety tolerance: Azf is safe tolerance, and adverse reactions are equivalent to placebo.

Regarding the clinical efficacy and safety of Azfdin, Professor Li Taisheng also said, "The Russian phase III clinical trial proves that Azf must reduce the occurrence of severity in international standards. , Repeated demonstrations of infectious disease experts. "

Compared with existing anti -new crown drugs, what advantages of Azf will have an advantage and the biggest difference?

At present, there are many new crown oral treatment drugs in the world, but there are still limitations such as potential genetic mutations, drug interaction, incomplete drugs and poor access to drugs.

Professor Chang Junbiao said that a drug is really successful, safe, effective, and quality controlled. New crown, this is also its unique biological characteristics.

Small dosage and appropriate price: Professor Chang Junbiao said that due to the special target and good drug activity, Azf's dosage of medication is very small, once a day, 5mg (1 mg/piece) once a day, which means Azf The price of single treatment for the treatment of new crowns is far lower than similar medicines. At present, Azf's fixed tablet is 270 yuan per bottle, which will greatly increase the availability of medicines.

Specifications and cure: Azf will only complete trioprosive acidization in the thymus, remove viruses in the thymus, and protect the immune system. The immune system also produces antiviral effects. Anti -virus is a "standard", and thymus protection is equivalent to "books". By inhibiting viruses and immunomically regulating dual -channel mechanisms, the symptoms and cure are managed to achieve the full management of people with light and medium -severe infections.

Is Azfding the first choice for preventing new crown pneumonia?

Early application of antiviral drugs is also one of the main points of the discussion of this meeting. "New Coronatte Pneumonia Diagnosis and Treatment Plan (Trial Ninth Edition)" emphasized that early antiviral treatment was a powerful weapon for patients to prevent severe illness and death. In the meeting, Professor Zhang Fujie also pointed out that the virus was highly copied in the early stage. Early antiviral treatment can control the transmission of virus and the progress of the disease. In the interpretation of the clinical trials of Azf's phase III, early applications can significantly reduce the patient's virus load and shorten the time of turning the yin, indicating that Azf can inhibit the duplication of virus in early infection in the new crown.

At the same time, Professor Wang Guiqiang, director of the Department of Infectious Diseases of the First Hospital of Peking University, also emphasized in an interview, "Due to the strong infectious infectiousness of the new crown virus, the treatment of antiviral therapy is expected to reduce the risk of transmission. It is also worth further clinical research after exposure."

Azf is included in the new crown diagnosis and treatment plan, which has enabled my country's new crown epidemic to prevent and control the new era of domestic special effects, which greatly enhances the ability of the Chinese medical service system to respond to the new crown.In the future, how can Azf will have more in -depth explorations in the combination of new crown prevention and control, and better help and control the epidemic prevention and control.Capture: Hu Haiyan

Edit: Wang Jia

- END -